Transfer of Cellular and Humoral Anti-Tumor Immunity with Immune T Cells After Stem Cell Transplant (SCT) for Metastatic Breast Cancer Following "Vaccination" with Anti-CD3 x Anti-Her2/Neu Bispecific Antibody (Her2Bi) Armed Activated T Cells

被引：0

作者：

Thakur, Archana ^{[1
]}

Al-Kadhimi, Zaid ^{[1
]}

Pray, Cassara ^{[2
]}

Tomaszewski, Elyse N. ^{[1
]}

Rathore, Ritesh ^{[3
]}

Steele, Patricia A. ^{[1
]}

Abidi, Muneer H. ^{[1
]}

Ayash, Lois ^{[1
]}

Schalk, Dana L. ^{[1
]}

Myers, Karen ^{[1
]}

Mitchell, Alice ^{[1
]}

Deol, Abhinav ^{[1
]}

Uberti, Joseph P. ^{[1
]}

Ratanatharathorn, Voravit ^{[1
]}

Lum, Lawrence G. ^{[1
]}

机构：

[1] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[2] Michigan State Univ, Coll Vet Med, E Lansing, MI 48824 USA

[3] Roger Williams Canc Ctr, Providence, RI USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：835 / 835

页数：1

共 50 条

[1] Activated T Cells (ATC) Armed with Anti-CD3 X Anti-Her2/Neu Bispecific Antibody (Her2Bi) Is a Potent Immunomodulator.
Norkina, Oxana
Thakur, Archana
Norkin, Maxim
Paul, Elyse
Al-Kadhimi, Zaid
Lum, Lawrence G.
BLOOD, 2008, 112 (11) : 888 - 888
[2] Combining anti-CD3 activated T cells armed with anti-CD3 x anti-Her2 bispecific antibody may provide an additional anti-tumor effect after stem cell transplant for breast cancer.
Sen, M
Wankowski, DM
Lum, LG
EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 743 - 743
[3] PRIMED AND BOOSTED ANTI-BREAST CANCER TUMOR IMMUNITY AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT): IN VIVO PRIMING WITH T CELLS ARMED WITH ANTI-CD3 X ANTI-HER2/NEU BISPECIFIC ANTIBODY (HER2BI) PRE PBSCT AND BOOSTING AFTER PBSCT WITH ACTIVATED T CELLS (ATC)
Lum, L. G.
Thakur, A.
Al-Kadhimi, Z.
Abidi, M.
Ayash, L.
Cummings, F.
Rathore, R.
Uberti, J. P.
Ratanatharathorn, V
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S166 - S166
[4] Fate and function of anti-CD3 activated T cells (ATC) armed with OKT3 x anti-Her2/Neu bispecific antibody (Her2Bi) in patients with Her2/neu+ tumors
Lum, L
Grabert, R
Gall, J
Kouttab, N
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S21 - S21
[5] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody I:: Anti-tumor activity and survival in SCID/Beige mice.
Smith, JA
Davol, PA
Kouttab, NM
Rathore, R
Elfenbein, GJ
Lum, LG
BLOOD, 2002, 100 (11) : 673A - 673A
[6] Phase I immunotherapy in women with metastatic breast cancer with activated T cells targeted with anti-CD3 x anti-Her2/neu bispecific antibody
Lum, L. G.
Al-Kadhimi, Z.
Skuba, C.
Sandborg, R.
Rathore, R.
Liu, Q.
Uberti, J. P.
Ratanatharathorn, V.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[7] Enhanced anti-breast cancer cyotoxicity, after autologous peripheral blood stem cell transplant (PBSCT) by boosting with multiple infusions of activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) prior to PBSCT
Lum, Lawrence G.
Al-Kadhimi, Zaid
Skuba, Cassara
Ratanatharathorn, Voravit
Uberti, Joseph P.
BLOOD, 2007, 110 (11) : 807A - 808A
[8] Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors
Sen, M
Wankowski, DM
Garlie, NK
Siebenlist, RE
Van Epps, D
LeFever, AV
Lum, LG
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (02): : 247 - 260
[9] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody III.: Kinetics and survival of armed ATC in prostate cancer patients.
Rathore, R
Colvin, GA
Kouttab, NM
Falvey, MT
Grabert, RC
Smith, JA
Tiggs, JC
Cohen, IC
Maizel, AL
Quesenberry, PJ
Elfenbein, GJ
Lum, LG
BLOOD, 2002, 100 (11) : 54B - 54B
[10] Activated T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody II.: Armed ATC target, kill, divide, and survive.
Grabert, RC
Smith, JA
Kouttab, NM
Tiggs, JC
Lum, LG
BLOOD, 2002, 100 (11) : 55B - 55B

← 1 2 3 4 5 →